ST. PAUL, Minn., Nov 16, 2010 (BUSINESS WIRE) --
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company and
ZONARE Medical Systems, a leading provider of premium ultrasound
systems, today announced they have entered into a development and
marketing agreement. Under this agreement, the companies will combine
the St. Jude Medical intracardiac echocardiography (ICE) catheter and
the ZONARE z.one Convertible Ultrasound system technology, and co-market
an ultrasound system for intracardiac (inside the heart) imaging. The
co-branded Ultrasound console will provide a new platform for the St.
Jude Medical ViewFlex ICE catheter to perform intracardiac imaging.
ZONARE's z.one Convertible Ultrasound system was introduced in 2005 and
uses Zone Sonography(TM) technology, a unique patented approach to
ultrasound imaging. To date, the company has sold over 4,000 z.one
"St. Jude Medical is pleased to partner with ZONARE Medical Systems and
to combine its innovative technology and promising future developments
in ultrasound imaging with our electrophysiology catheters," said Jane
J. Song, president of the St. Jude Medical Atrial Fibrillation Division.
"We are also pleased to be partnering with a company that is focused on
developing ultrasound technology and integrating it with our catheters."
Ultrasound technology allows physicians to produce high-resolution
intracardiac images. These images help guide physicians in performing a
variety of procedures such as radiofrequency (RF) ablation to treat
irregular heart rhythms and in closing defects such as patent foramen
ovale (PFO), a small hole or opening in the wall between the two upper
chambers of the heart (the atria). Clear views inside the heart also
help reduce the time that it takes physicians to perform such
procedures, providing patients an opportunity to recover more quickly
and potentially enhancing hospital productivity.
Ultrasound imaging systems work by transmitting high-frequency sound
waves through a transducer on the tip of a catheter. The sound waves
reflect off structures inside the heart and the transducer collects and
converts them back into electric energy to produce anatomical images.
This ultrasound imaging process can also help to eliminate unnecessary
fluoroscopy (X-ray) exposure to the patient and physician.
"We are pleased to partner with St. Jude Medical to develop better tools
for increased clinician confidence when performing complex
electrophysiology procedures," said Jay D. Miller, president and chief
executive officer of ZONARE. "This continues to validate ZONARE's
exclusive focus on innovative software-based ultrasound and transducer
technologies designed to deliver premium image quality in a compact and
light-weight ultrasound system."
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on
putting more control into the hands of those who treat cardiac,
neurological and chronic pain patients worldwide. The company is
dedicated to advancing the practice of medicine by reducing risk
wherever possible and contributing to successful outcomes for every
patient. St. Jude Medical is headquartered in St. Paul, Minn. and has
four major focus areas that include: cardiac rhythm management, atrial
fibrillation, cardiovascular and neuromodulation. For more information,
please visit sjm.com.
About ZONARE Medical Systems, Inc.
ZONARE Medical Systems, Inc., based in Mountain View, Calif, is
committed to ultrasound excellence through its innovative,
software-based, next generation technology, and by putting customers and
employees first. The patented design and architecture of the z.one
Ultrasound(TM) platform deliver premium image quality and clinical
versatility at unparalleled value. ZONARE's exclusive ultrasound focus
has resulted in achieving a user loyalty rating of 100 percent in the
KLAS Top 20: 2009 Year-End Report. All ZONARE customers interviewed for
this ultrasound market report indicated that they would purchase a z.one
ultrasound system again. For more information, visit: www.zonare.com.
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the Company, including potential
clinical successes, anticipated regulatory approvals and future product
launches, and projected revenues, margins, earnings and market shares.
The statements made by the Company are based upon management's current
expectations and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those described in
the forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company's control and the
risk factors and other cautionary statements described in the Company's
filings with the SEC, including those described in the Risk Factors and
Cautionary Statements sections of the Company's Quarterly Report on Form
10-Q for the fiscal quarter ended October 2, 2010. The Company does not
intend to update these statements and undertakes no duty to any person
to provide any such update under any circumstance.
SOURCE: St. Jude Medical, Inc.
St. Jude Medical, Inc.
J.C. Weigelt, 651-756-4347
Amy Jo Meyer, 651-756-3029